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ABSTRACT
Poor placentation, which manifests as pre-eclampsia and fetal growth restriction, is a major pregnancy complication.
The underlying cause is a deﬁciency in normal trophoblast invasion of the spiral arteries, associated with placental
inﬂammation, oxidative stress, and an antiangiogenic state. Peripartum therapies, such as prenatal maternal
corticosteroids and magnesium sulphate, can prevent some of the adverse neonatal outcomes, but there is currently
no treatment for poor placentation itself. Instead, management relies on identifying the consequences of poor
placentation in the mother and fetus, with iatrogenic preterm delivery to minimise mortality and morbidity. Several
promising therapies are currently under development to treat poor placentation, to improve fetal growth, and to
prevent adverse neonatal outcomes. Interventions such as maternal nitric oxide donors, sildenaﬁl citrate, vascular
endothelial growth factor gene therapy, hydrogen sulphide donors, and statins address the underlying pathology,
while maternal melatonin administration may provide fetal neuroprotection. In the future, these may provide a range
of synergistic therapies for pre-eclampsia and fetal growth restriction, depending on the severity and gestation of
onset. © 2014 The Authors. Prenatal Diagnosis published by John Wiley & Sons Ltd.
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for Health Research University College London Hospitals Biomedical Research Centre.
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INTRODUCTION
In normal pregnancy, trophoblast invasion of the maternal
spiral arteries produces a low-resistance, high-ﬂow maternal
uterine circulation. These changes are enhanced by the
placental production of vasoactive substances, such as
vascular endothelial growth factor (VEGF) and placental
growth factor (PlGF). VEGF and, to a lesser extent, PlGF cause
angiogenesis and activate endothelial nitric oxide synthase
(eNOS) to produce nitric oxide (NO) and hence vasodilatation.
In contrast, poor placentation appears to arise from
interactions between inadequate trophoblast invasion, leading
to reduced placental perfusion, and oxidative stress, resulting
in the production of inﬂammatory cytokines.1,2 Recent
evidence from a study of placental bed biopsies in pregnancies
affected by fetal growth restriction (FGR) and pre-eclampsia
conﬁrms that there is a major defect in myometrial spiral
artery remodelling that is linked to clinical parameters.3
Although the sequence and relative contributions of the
defects are unclear, the result is a relative reduction in uterine
artery blood ﬂow,3,4 an increase in the soluble VEGF receptor
soluble fms-like tyrosine kinase 1 (sFlt-1), and a reduction in
the available maternal VEGF and PlGF.1,2,5,6 Other synergistic
antiangiogenic proteins such as soluble endoglin are
increased, leading to inhibition of transforming growth
factor-β signalling. The phenotype is thus attributable to an
antiangiogenic state.7
Other articles in this review have considered whether we can
predict and prevent poor placentation. This article will focus
on strategies to treat poor placentation and prevent the
adverse outcomes it produces.
HOW CAN WE TREAT POOR PLACENTATION?
Currently, there is no treatment for poor placentation once it
has developed. The maternal manifestations of pre-eclampsia
may be manageable in the short term, but the only way to cure
pre-eclampsia, and prevent stillbirth and severe in utero
neurological damage in FGR, is to deliver the fetus and
placenta. Depending upon gestation, this may mean very
preterm delivery, with its own associated complications.
Numerous interventions have been investigated, including
bed rest, betamimetics, calcium channel blockers, oxygen or
nutrient supplementation, and antioxidants such as vitamins
C and E. In all cases, systematic reviews have not found
sufﬁcient evidence to evaluate or recommend their use,
possibly because they do not address the root of the problem:
antiangiogenesis.8–14 Despite the many challenges in
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developing obstetric therapies and relative underinvestment
from the pharmaceutical industry, a number of promising
interventions are now emerging, many from academic-
industrial partnerships (Figure 1).
Nitric oxide donors
Several studies have looked at the effects of the organic nitrates
glyceryl trinitrate and isosorbide dinitrate in women with pre-
eclampsia.15 These have demonstrated a reduction in maternal
blood pressure, uterine artery pulsatility index and resistance
index, and umbilical artery resistance index with no evidence
of adverse effects on fetal heart rate. The studies have been
small, however, with only three randomised trials, which were
powered to look at short-term haemodynamic changes rather
than outcome.16–18 Furthermore, organic nitrates are
associated with tolerance, requiring nitrate-free periods. An
alternative NO donor, S-nitrosoglutathione (GSNO), does not
produce tolerance, reduces platelet aggregation, and increases
the antioxidant glutathione.15 A phase I study in women with
early-onset pre-eclampsia (21–33weeks of gestation, n= 10),
in which eight of the fetuses were classiﬁed as growth
restricted, found that GSNO signiﬁcantly reduced maternal
blood pressure and uterine artery resistance index without
affecting fetal Doppler measurements.19 Furthermore, a recent
dose ranging study found that GSNO could reduce small vessel
tone, platelet activation, and proteinuria at doses that did not
signiﬁcantly reduce maternal mean arterial pressure.20 Larger
studies are now needed to determine whether NO donors can
produce clinically meaningful differences in outcome.
Sildenaﬁl citrate
The phosphodiesterase-5 inhibitor sildenaﬁl produces its
vasodilatatory effects by preventing the breakdown of NO.
Initial evidence to support its use as a therapy for poor
placentation came from in vitro myography studies;
myometrial vessels from women with pre-eclampsia exhibited
signiﬁcantly less relaxation than healthy controls, but
relaxation increased after exposure to sildenaﬁl citrate.21 These
ﬁndings were replicated in myometrial vessels from
pregnancies affected by FGR in the absence of pre-eclampsia.22
Unfortunately, results from a double-blind randomised
placebo-controlled trial in women diagnosed with early-onset
pre-eclampsia (24–34weeks of gestation, n= 35) were
disappointing.23 Sildenaﬁl was well tolerated, with no increase
in maternal or fetal adverse events, but it did not increase the
interval to delivery, possibly because the pathological process
was too advanced. In addition, a dose escalation design meant
over half of the women received only the lowest dose of 20mg
three times a day (TDS). No difference was found in the
vascular reactivity of myometrial vessels from women receiving
sildenaﬁl compared with placebo, possibly because of the
interval between the last dose and delivery.24
Results of more recent pre-clinical studies, however,
have been promising. The catechol-O-methyltransferase
(COMT-/-) knockout mouse model of poor placentation
results in increased umbilical artery pulsatility index (UAPI)
and smaller and lighter pups compared with controlled mice.25
However, COMT-/- mice given sildenaﬁl from 12.5 to 18.5 days
postconception (dpc) had signiﬁcantly higher pup weight,
crown-rump length, and abdominal circumference (AC) than
untreated COMT-/- mice and signiﬁcantly lower UAPI. This
effect of sildenaﬁl on fetal growth was not replicated in a study
using the rat reduction of uteroplacental perfusion pressure
(RUPP) model, which involves clipping the maternal aorta
and ovarian arteries at 14 dpc (term= 22dpc), resulting in
maternal hypertension, an increase in sFlt-1 and oxidative
stress, and a reduction in free VEGF and fetal weight.26
However, RUPP dams receiving sildenaﬁl did have a
signiﬁcantly lower mean arterial pressure than untreated
RUPP dams.
Figure 1 Sites of action of the interventions currently under investigation as treatments for established poor placentation. sFlt-1, soluble fms-like
tyrosine kinase 1; VEGF, vascular endothelial growth factor; NOS, nitric oxide synthase; NO, nitric oxide; sGC, soluble guanylate cyclase;
GTP, guanosine-5′-triphosphate; cGMP, cyclic guanosine monophosphate; 5′ GMP, guanosine monophosphate; PDE5, phosphodiesterase
type 5 inhibitor
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The potential for sildenaﬁl to improve fetal growth was
investigated in an open-label pilot study.27 Ten women with
pregnancies affected by severe early-onset ‘dismal prognosis’
FGR, where the chance of intact fetal survival was felt to be less
than 50%, accepted the option of taking 25-mg sildenaﬁl TDS.
Outcomes were compared with those from matched
contemporaneous sildenaﬁl-naive pregnancies (n= 17).
Sildenaﬁl treatment was associated with increased
posteligibility fetal growth velocity in the AC [9/10 (treated) vs
7/17 (naive); odds ratio, 12.9; 95% CI, 1.3, 126]. In the tenth
sildenaﬁl-treated pregnancy, where umbilical artery end
diastolic ﬂow was already reversed, stillbirth ensued within
24h of starting the intervention. No maternal adverse effects
were reported, although a greater proportion of treated women
developed pre-eclampsia. Overall, there was a trend towards
improved perinatal survival in the sildenaﬁl-treated group;
however, it is unclear if the higher levels of termination and
permissive stillbirth in the sildenaﬁl-naive group reﬂect poorer
prognosis or altered management.
The effects of sildenaﬁl in early-onset FGR are being
addressed by the STRIDER NZAus trial, starting shortly in
Australia and New Zealand (Table 1). This phase II double-
blind randomised placebo-controlled trial will look at the effect
of 50-mg oral sildenaﬁl TDS on fetal growth velocity in FGR
diagnosed before 30weeks of gestation. Secondary outcomes
will include rates of perinatal mortality and intact survival. A
UK version of the trial is also in development.
Maternal VEGF gene therapy
An alternative approach to treating poor placentation is to
increase the levels of VEGF in the maternal uterine arteries,
thus improving local vasodilatation and angiogenesis. This
can be achieved with an adenoviral (Ad) gene therapy vector,
either injected into the uterine arteries or applied to the
outside of the vessels, which produces short-term VEGF
expression (Ad.VEGF). Studies in large and small animals have
conﬁrmed the efﬁcacy of this approach for improving fetal
growth in FGR. In normal sheep pregnancy, injection of Ad.
VEGF (1 × 1011 particles), compared with injection of a control
non-vasoactive vector (Ad.LacZ), increased uterine artery
volume blood ﬂow within 7 days of injection. VEGF expression
in the perivascular adventitia of the treated vessels was
associated with reduced uterine artery contractile response,
increased uterine artery relaxation response, and increased
expression of eNOS, inducible NOS, and VEGF receptor 2.28
In long term, this increase in ﬂow persisted for at least 4weeks
until the end of gestation. Although no VEGF expression
remained, the reduced contractile responses of the uterine
artery persisted and periadventitial blood vessels were
signiﬁcantly increased, suggesting that the on-going
improvement in uterine blood ﬂow was mediated by vascular
remodelling.29 Importantly, there was no evidence of vector
spread or expression in fetal tissues and no effect of the vector
on maternal or fetal haemodynamic measures. In a sheep
model of FGR, overnourishment of pregnant adolescent ewes
results in approximately half of the fetuses demonstrating
marked asymmetric growth restriction with increased
umbilical artery Doppler indices and reduced placental
expression of VEGF.30–32 Overnourished adolescent dams were
randomised to receive Ad.VEGF, Ad.LacZ, or saline, injected
into both uterine arteries. The fetal growth velocity, as
determined by ultrasound measurement of AC, was
signiﬁcantly increased in the Ad.VEGF group compared with
the Ad.LacZ or saline groups by 3 to 4weeks after injection,
and there appeared to be amelioration of fetal brain sparing.33
At necropsy, signiﬁcantly fewer fetuses demonstrated marked
FGR in the Ad.VEGF group than in the Ad.LacZ or saline
groups. Increased fetal growth velocity was conﬁrmed in a
second experimental group, administering overnourished
adolescent dams uterine artery injections of either Ad.VEGF
or saline.34 Results from treatment in FGR guinea pig
pregnancy suggest a similar improvement in fetal growth
velocity.35
In the clinical context, vector delivery into the uterine
arteries could be achieved through interventional radiology,
which is supported by the Royal College of Obstetricians and
Gynaecologists as a prophylactic measure before delivery in
women at high risk of postpartum haemorrhage.36 While this
is more invasive than administering oral medication, it has
the potential advantage of targeting vasoactive changes to the
maternal uteroplacental circulation. The EVERREST Project,
which started in 2013, aims to carry out a phase I/IIa clinical
trial to assess the safety and efﬁcacy of maternal uterine artery
Ad.VEGF gene therapy for severe early-onset FGR. The project,
funded by the European Union, involves a multinational,
multidisciplinary consortium, including experts in bioethics,
fetal medicine, fetal therapy, obstetrics, and neonatology.
Hydrogen sulphide donors
Hydrogen sulphide (H2S), like NO, is a vasorelaxant and pro-
angiogenic gas. H2S produces vasodilatation by acting on
smooth muscle cell adenosine triphosphate-sensitive
potassium channels, while its angiogenic effects appear to be
mediated by VEGF and the VEGF receptor 2.37 Placentas from
pregnancies affected by FGR or pre-eclampsia with abnormal
umbilical Dopplers have reduced expression of the enzyme
cystathionine-gamma-lyase, which produces H2S.
38 The H2S
donor sodium hydrosulﬁde (NaHS) decreases vascular
resistance in healthy placentas38 and mitigates the
antiangiogenic effects of sFlt-1 in vitro.39 In rats with a pre-
eclampsia-like phenotype induced by systemic Ad.sFlt-1
vector, intraperitoneal injection of NaHS was associated with
signiﬁcantly reduced maternal hypertension, proteinuria, and
sFlt-1 levels and signiﬁcantly increased VEGF levels compared
with inert control injections.39 This was without any apparent
adverse effects on pup growth or development. Further work
is now needed to investigate the therapeutic potential of H2S
donors in poor placentation.
Statins
3-Hydroxyl-3-methylglutaryl coenzymeA reductase inhibitors, or
statins, are best known for their lipid-modifying cardioprotective
effects. However, they are also antiinﬂammatory, antioxidant,
and may beneﬁcially modify the pathways of poor placentation.
In mice administered Ad.sFlt-1 at 8 dpc, which produces a
pre-eclampsia-like phenotype and increased vascular
Treatment of poor placentation and prevention of adverse outcomes 679
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reactivity, maternal oral pravastatin from 9 to 18 dpc reduced
the elevated sFlt-1 levels and reduced vascular contractility at
18 dpc (term= 21dpc) compared with untreated Ad.sFlt-1
mouse controls.40 Similarly in the rat RUPP model, oral
pravastatin administration to RUPP dams from 14 to 19 dpc
ameliorated maternal hypertension and resulted in decreased
sFlt-1, increased free VEGF, and increased fetal weight
compared with untreated RUPP dams, giving comparable
results to normal pregnant controls.41
Early concerns about possible teratogenicity with statins
have not been supported by more recent population exposure
studies, which have found no increase in congenital anomalies
with statin use in pregnancy.42,43 Pravastatin is the most
hydrophilic statin, which should limit placental transfer, but
even so some transplacental passage does occur.44 Because
statins increase NO bioavailability, this could potentially
interfere with the preferential redistribution of fetal cardiac
output to the brain, which is often seen with poor
placentation. To address this question, the effect of
intravenous fetal pravastatin administration was studied in
sheep before, and 24h after, 30min of maternal acute hypoxia,
designed to achieve a 50% reduction in the partial pressure of
oxygen in the fetus.45 Although fetal exposure to pravastatin
reduced indices of anaerobic metabolism such as lactate,
which might be beneﬁcial, it also diminished the
vasoconstrictor responses to acute hypoxia, which might be
deleterious for the fetus. This suggests that until further
evidence is available, statins should be used with caution in
pregnancy, particularly when poor placentation is evident.
In the UK, a double-blind, randomised placebo-controlled
trial is currently studying the effect of pravastatin in women
diagnosed with early-onset pre-eclampsia between 24 and
31 + 6weeks of gestation (Table 1). The primary outcome
measure is maternal sFlt-1 levels at 48 h after randomisation,
with information also collected on maternal and neonatal
mortality and morbidity. Another on-going double-blind,
randomised placebo-controlled trial in the United States is
investigating the safety and pharmacokinetics of pravastatin
between 12 and 16 + 6weeks of gestation in women with a
history of pre-eclampsia (Table 1).46
Plasma exchange and plasmaphaeresis
As many of the maternal manifestations of pre-eclampsia are
produced by soluble mediators, removal of these factors is
under investigation as a potential treatment. Plasma exchange,
which is non-speciﬁc and non-selective, produced no beneﬁt
in early-onset pre-eclampsia (24–30weeks of gestation,
n= 7).47 Instead, it was associated with an initial worsening of
hypertension, large volume ascites, pulmonary oedema,
pleural effusions, and the need for delivery in all cases within
48h of the intervention. Further studies using more selective
approaches have shown potential beneﬁt. Heparin-mediated
extracorporeal LDL precipitation (HELP) removes a range of
molecules including pro-atherogenic lipids, endothelin-1,
tumour necrosis factor-alpha, homocysteine, and ﬁbrinogen.
In a pilot study in early-onset pre-eclampsia (24–32weeks of
gestation, n= 9) between one and seven sessions of HELP
produced an improvement in blood pressure, proteinuria,
and oedema in eight of the nine women, with an average
interval to delivery of 17.7 days.48 More recently, dextran
sulphate column aphaeresis was found to remove circulating
sFlt-1 in women with pre-eclampsia.49 In three women who
received repeated aphaeresis, the pregnancies were continued
for 11 to 23 days. In some cases, however, aphaeresis reduced
maternal blood pressure, with or without a fall in fetal heart
rate. This resolved with maternal ﬂuid administration, but it
is unclear how growth-restricted fetuses might have
responded, and further studies using longer term outcome
endpoints are required.
WHAT PRENATAL TREATMENTS CAN PREVENT THE
ADVERSE OUTCOMES OF POOR PLACENTATION?
In the absence of a treatment, current obstetric practice offers
some interventions to mitigate the adverse effects of poor
placentation. Where iatrogenic preterm delivery is required,
the use of prenatal corticosteroids to encourage fetal lung
maturation and prevent respiratory distress syndrome50 and
magnesium sulphate to reduce cerebral palsy, preserve gross
motor function,51–53 and prevent eclampsia in at risk women
is clearly of beneﬁt.54–56 Interventions to promote smoking
cessation should be offered where applicable,57 as smoking in
the second and third trimester is associated with lower fetal
weight, abruption, and poor neonatal outcome,58 which
improves with smoking cessation.59–61 However, with the
development of new prenatal interventions, it may become
possible to further protect the fetus from the adverse
intrauterine environment associated with poor placentation.
Melatonin
Melatonin is a lipid soluble hormone released by the pineal
gland, which has vasoactive, antioxidant, and immune-
modulating properties. In newborns, it may have a
neuroprotective effect following perinatal asphyxia,62 and
melatonin administration during pregnancy is currently being
investigated in the context of poor placentation, especially for
its potential to reduce oxidative stress.
In a rat model of FGR, where maternal nutrient restriction
from 15dpc signiﬁcantly reduces pup birthweight, maternal
administration of melatonin from 15dpc was associated with
increased birthweight, comparable with that of control pups,
and increased expression of the antioxidant enzymes
magnesium superoxide dismutase and catalase.63 This effect
was not replicated in amaternal nutrient restriction sheepmodel
of FGR, where maternal melatonin treatment was associated
with a non-signiﬁcant reduction in fetal weight compared with
control untreated nutrient-restricted dams and no difference in
malondialdehyde (MDA), a marker of oxidative stress.64
However, maternal melatonin administration was associated
with a signiﬁcant increase in umbilical artery blood ﬂow, both
in adequately fed and nutrient-restricted dams, suggesting that
it might have a beneﬁcial effect on placental resistance.
A subsequent study used single umbilical artery ligation
(SUAL) in sheep at 105 to 110 dpc (term=145dpc) to create
asymmetric FGR, moderate fetal hypoxaemia, widespread
white matter injury, and newborn developmental delay.65
Intravenous maternal melatonin administration starting 4 h
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after SUAL did not affect fetal growth but did signiﬁcantly
reduce markers of oxidative stress in the cerebral cortex and
improve the time taken to achieve neonatal behavioural
milestones, such as suckling.
A pilot study is currently on-going in Australia to investigate
the effect of maternal melatonin administration on oxidative
stress in pregnancies affected by FGR (Table 1).66 So far, six
women have received melatonin with no adverse maternal or
fetal effects, and this was associated with a signiﬁcant
reduction in placental MDA concentration compared with
untreated women.65 A further Australian trial will be
investigating whether maternal melatonin administration can
delay the interval to delivery following a diagnosis of preterm
pre-eclampsia (Table 1).67
N-acetylcysteine
N-acetylcysteine (NAC) scavenges reactive oxygen species and
forms the antioxidant glutathione, thereby counteracting
oxidative stress and increasing the bioavailability of NO.68 In
the rat RUPP model, NAC alleviated the rise in maternal blood
pressure and increased pup brain weight when given from the
time of arterial ligation.69 However, a small double-blind
randomised controlled trial of NAC in early-onset severe
pre-eclampsia or haemolysis, elevated liver enzymes, and low
platelet count syndrome (HELLP) (25–33weeks of gestation,
n=38) showed no difference in the interval to delivery, maternal
complications, or neonatal outcome.70 This may be because it
was too late in the disease course to be of beneﬁt or because
the dose of 600mg TDS was not high enough. More recently, in
a guinea pig model of maternal chronic hypoxia, administration
of NAC did not affect pup weight but did ameliorate oxidative
stress responses to hypoxia in the fetal liver.71 Further research
is needed to investigate whether NAC may be useful in
preventing fetal complications of poor placentation.
HOW CAN NOVEL THERAPIES BE TRANSLATED INTO THE
CLINIC?
To achieve real beneﬁt for the future health of pregnant
women, effective therapies must be brought from the realm
of research into clinical practice. This process is hampered,
however, by the reluctance of the pharmaceutical industry to
invest in the development of new obstetric drugs or to licence
existing drugs for use in pregnancy.72 This reluctance may arise
from a fear of litigation combined with the practical and ethical
complexity of conducting obstetric clinical trials, which must
take into account not only the pregnant woman, the fetus,
and long-term neonatal follow-up but also the diseases that
currently have heterogeneous manifestations and
unpredictable clinical progression. To some extent, safety
considerations can be addressed with a ﬁrm basis of pre-
clinical evidence. Ideally, this should include reproductive
toxicology studies and evidence of efﬁcacy in an animal model
of the disease, taking into account species differences in
placental structure and function as well as the timing of
different stages of organ development.73,74 However, real
progress will require greater recognition that excluding
pregnant women from clinical trials does not protect them
from risk but rather unfairly disadvantages them by restricting
their access to evidence-based medicine.75–77
CONCLUSION
Poor placentation causes signiﬁcant maternal, fetal, and
neonatal health problems in the short and long term. While
clinicians currently have a handful of perinatal interventions
to mitigate the adverse effects of poor placentation and
associated iatrogenic preterm delivery, there are, as yet, no
interventions that can increase fetal growth. An increasing
understanding of the interlinked antiangiogenic mechanisms
that underlie poor placentation, and its manifestation as
pre-eclampsia and FGR, is allowing us to identify potential
therapeutic targets. Translation into the clinic is complex and
will require dialogue between patients, stakeholders,
clinicians, and the regulators to ensure that the best possible
outcomes are attained. The therapies that are currently being
developed and tested offer hope for the future management
of pregnancies affected by poor placentation, as well as
providing a framework for the advancement of obstetric
therapies as a whole.
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WHAT’S ALREADY KNOWN ABOUT THIS TOPIC?
• Poor placentation results in stillbirth, neonatal neurological,
respiratory and gastrointestinal damage, and long-term health
problems for affected women and surviving children.
• As yet, there is no treatment that can increase fetal growth in utero.
WHAT DOES THIS STUDY ADD?
• A number of therapies are showing potential to treat poor
placentation, to improve fetal growth, and to prevent adverse
neonatal outcomes. Clinical trials are planned or in progress to
evaluate their safety and efﬁcacy.
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